SCHEMBL5563443

SCHEMBL5563443

CCOc1cc(NC(=O)OC(C)(C)C)c(N)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 1/20 0.43
MITF O75030 1/20 0.43
THRB P10828 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
RORC P51449 1/20 0.42
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
RECQL P46063 1/20 0.39
AAK1 Q2M2I8 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 2/20 0.37
HTT P42858 1/20 0.37
MAPKAPK2 P49137 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5557597 0.86 AAK1 (0.41) KDM4ETHRBALDH1A1AAK1L3MBTL1
SCHEMBL3571997 0.83 CA12 (0.41) AAK1MAPKAPK2
SCHEMBL2316733 0.82 AAK1 (0.41) KDM4ENPC1MITFTHRBMAPK1
SCHEMBL5562021 0.81 GAA (0.42) KDM4ENPC1MITFTHRBMAPK1
SCHEMBL5558047 0.80 CD44 (0.42) KDM4EALDH1A1AAK1LMNA
SCHEMBL20031372 0.80 NPC1 (0.43) KDM4ENPC1MITFTHRBMAPK1
SCHEMBL2353023 0.79 AAK1 (0.40) RORCAAK1HTT
SCHEMBL6250449 0.79 SMN1; SMN2 (0.43) KDM4ENPC1MITFTHRBMAPK1
SCHEMBL6164866 0.79 KDM4E (0.37) KDM4ENPC1RAB9AAAK1MAPKAPK2
SCHEMBL6165182 0.78 AAK1 (0.36) ALDH1A1AAK1LMNAMAPKAPK2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 KDM4E 1160/4885NPC1 1530/4885MITF 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.